- Home
- SBFM vs CANF Comparison
SBFM vs CANF Comparison
Compare SBFM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBFM | CANF |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SBFM | CANF |
|---|---|---|
| Price | $1.17 | $4.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $9,750.00 |
| AVG Volume (30 Days) | 36.6K | ★ 72.5K |
| Earning Date | 03-31-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,323,742.00 | $560,000.00 |
| Revenue This Year | $10.26 | $461.72 |
| Revenue Next Year | $32.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | N/A |
| 52 Week Low | $1.15 | $3.36 |
| 52 Week High | $3.90 | $46.60 |
Technical Indicators
Market Signals| Indicator | SBFM | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 68.57 |
| Support Level | $1.15 | $4.02 |
| Resistance Level | $1.23 | $4.74 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 10.00 | 71.62 |
Price Performance
Historical ComparisonAbout SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.